CN114007698B - 作为egfr抑制剂的大环化合物和衍生物 - Google Patents

作为egfr抑制剂的大环化合物和衍生物 Download PDF

Info

Publication number
CN114007698B
CN114007698B CN202080045795.1A CN202080045795A CN114007698B CN 114007698 B CN114007698 B CN 114007698B CN 202080045795 A CN202080045795 A CN 202080045795A CN 114007698 B CN114007698 B CN 114007698B
Authority
CN
China
Prior art keywords
alkyl
egfr
cancer
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080045795.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN114007698A (zh
Inventor
H·恩格尔哈特
D·博思
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN114007698A publication Critical patent/CN114007698A/zh
Application granted granted Critical
Publication of CN114007698B publication Critical patent/CN114007698B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080045795.1A 2019-06-24 2020-06-23 作为egfr抑制剂的大环化合物和衍生物 Active CN114007698B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19181952.3 2019-06-24
EP19181952 2019-06-24
PCT/EP2020/067451 WO2020260252A1 (en) 2019-06-24 2020-06-23 New macrocyclic compounds and derivatives as egfr inhibitors

Publications (2)

Publication Number Publication Date
CN114007698A CN114007698A (zh) 2022-02-01
CN114007698B true CN114007698B (zh) 2024-01-09

Family

ID=67003267

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080045795.1A Active CN114007698B (zh) 2019-06-24 2020-06-23 作为egfr抑制剂的大环化合物和衍生物

Country Status (5)

Country Link
US (1) US12522615B2 (https=)
EP (1) EP3986564A1 (https=)
JP (1) JP7590996B2 (https=)
CN (1) CN114007698B (https=)
WO (1) WO2020260252A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4079735B1 (en) 2019-12-16 2025-08-06 Beijing Tide Pharmaceutical Co., Ltd. Macrocyclic compounds for inhibiting and inducing degradation of egfr kinase in the treatment of cancer
CN113880804A (zh) * 2020-07-01 2022-01-04 微境生物医药科技(上海)有限公司 新型苯并咪唑化合物
CN114163454B (zh) * 2020-09-11 2026-01-02 上海翰森生物医药科技有限公司 含吡啶多环类衍生物抑制剂、其制备方法和应用
WO2022098992A1 (en) * 2020-11-05 2022-05-12 Scorpion Therapeutics, Inc. Use of macrocyclic compounds in methods of treating cancer
CN114057771B (zh) * 2020-12-03 2023-10-03 北京鞍石生物科技有限责任公司 大环化合物及其制备方法和应用
CN114656482B (zh) * 2020-12-23 2025-10-17 南京圣和药业股份有限公司 作为egfr抑制剂的大环杂环类化合物及其应用
CN116761603A (zh) * 2021-02-06 2023-09-15 正大天晴药业集团股份有限公司 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途
CN114907379B (zh) * 2021-02-06 2026-04-17 正大天晴药业集团股份有限公司 作为egfr激酶抑制剂的大环化合物
AU2022230397A1 (en) * 2021-03-02 2023-09-21 Dana-Farber Cancer Institute, Inc. Covalent egfr inhibitors and methods of use thereof
IL306067A (en) * 2021-03-26 2023-11-01 Theseus Pharmaceuticals Inc Macrocyclic egfr inhibitors for the treatment of cancer
TW202309022A (zh) 2021-04-13 2023-03-01 美商努法倫特公司 用於治療具egfr突變之癌症之胺基取代雜環
CN115368378B (zh) * 2021-05-21 2024-11-19 深圳市塔吉瑞生物医药有限公司 取代的大环化合物及包含该化合物的组合物及其用途
IL309040A (en) * 2021-06-30 2024-02-01 Aqilion Ab Macrocyclic TAK1 inhibitors
WO2023001069A1 (zh) * 2021-07-23 2023-01-26 南京明德新药研发有限公司 大环酰胺类化合物及其应用
TW202330550A (zh) * 2021-11-30 2023-08-01 大陸商正大天晴藥業集團股份有限公司 含有環烷基或鹵代烷基的化合物
US20250282795A1 (en) * 2022-04-20 2025-09-11 Celyn Therapeutics, Inc. EGFR Inhibitors in cancer treatment
CN117024443A (zh) * 2022-05-09 2023-11-10 元启(苏州)生物制药有限公司 Egfr抑制剂及其用途
CN119522227A (zh) * 2022-07-21 2025-02-25 贝达药业股份有限公司 大环化合物及其药物组合物和应用
CN119487039A (zh) 2022-07-21 2025-02-18 贝达药业股份有限公司 大环化合物及其药物组合物和应用
TW202416963A (zh) * 2022-09-02 2024-05-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｅｇｆｒ抑制劑及其用途
WO2024078263A1 (zh) * 2022-10-09 2024-04-18 药雅科技(上海)有限公司 大环杂环类化合物作为egfr抑制剂的制备及其应用
CN117229300A (zh) * 2023-03-12 2023-12-15 药雅科技(上海)有限公司 Egfr抑制剂的制备及其应用
WO2024099402A1 (en) * 2022-11-10 2024-05-16 Beigene (Beijing) Co., Ltd. Intermediates and process of compounds for the degradation of egfr kinase
WO2024099400A1 (en) * 2022-11-10 2024-05-16 Beigene (Beijing) Co., Ltd. Intermediates and process of compounds for the degradation of egfr kinase
TW202428267A (zh) * 2022-11-10 2024-07-16 英屬開曼群島商百濟神州有限公司 用於降解ｅｇｆｒ激酶之化合物
CN118324778A (zh) * 2023-04-25 2024-07-12 苏州共康医药科技有限公司 第四代egfr抑制剂
EP4720071A1 (en) * 2023-05-31 2026-04-08 Beone Medicines I GmbH Compounds for the degradation of egfr kinase

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159742A (zh) * 2011-12-16 2013-06-19 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
CN104379575A (zh) * 2012-06-06 2015-02-25 Irm责任有限公司 用于调节egfr活性的化合物和组合物
CN104520291A (zh) * 2012-06-06 2015-04-15 Irm责任有限公司 用于调节egfr活性的化合物和组合物
CN105008371A (zh) * 2013-02-07 2015-10-28 默克专利股份公司 大环哒嗪酮衍生物
WO2018005860A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018112111A1 (en) * 2016-12-13 2018-06-21 Health Research, Inc. Epidermal growth factor receptor (egfr) targeted photosensitizers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132438B2 (en) 2001-10-09 2006-11-07 Amgen Inc. Benzimidazole derivatives
JP2005509003A (ja) 2001-11-09 2005-04-07 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼインヒビターとして有用なベンゾイミダゾール化合物
EP1388341A1 (en) 2002-08-07 2004-02-11 Aventis Pharma Deutschland GmbH Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
AU2003257094A1 (en) 2002-08-08 2004-02-25 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
WO2005070420A1 (en) 2004-01-14 2005-08-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
WO2005079791A1 (en) 2004-02-12 2005-09-01 Boehringer Ingelheim Pharmaceuticals, Inc. Thiophene -2- carboxylic acid - (1h - benzimidazol - 2 yl) - amide derivatives and related compounds as inhibitors of the tec kinase itk (interleukin -2- inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
WO2007133983A2 (en) 2006-05-08 2007-11-22 Pharmacopeia, Inc. 2-aminobenzimidazoles for treating neurodegenerative diseases
SG10201505997TA (en) 2010-08-05 2015-09-29 Amgen Inc Benzimidazole And Azabenzimidazole Compounds That Inhibit Anaplastic Lymphoma Kinase
US9573958B2 (en) * 2012-08-31 2017-02-21 Principia Biopharma, Inc. Benzimidazole derivatives as ITK inhibitors
WO2014081718A1 (en) 2012-11-20 2014-05-30 Genentech, Inc. Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
CA2943220C (en) 2014-03-20 2024-01-16 Capella Therapeutics, Inc. Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
JP6568926B2 (ja) 2014-03-20 2019-08-28 カペラ セラピューティクス，インコーポレーテッド 癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
WO2016176473A1 (en) 2015-04-28 2016-11-03 Sanford-Burnham Medical Researc Institute Apelin receptor agonists and methods of use thereof
CN108012529A (zh) 2015-05-15 2018-05-08 诺华股份有限公司 治疗egfr突变的癌症的方法
JP6845165B2 (ja) 2015-06-30 2021-03-17 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｅｇｆｒ阻害剤およびその使用方法
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
BR112018003812B1 (pt) 2015-09-18 2024-04-30 Merck Patent Gmbh Compostos de heteroarila como inibidores de irak, seu uso, composição farmacêutica, e kit
CN108602776B (zh) 2015-09-18 2021-12-03 默克专利有限公司 用作irak抑制剂的杂芳基化合物及其用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103159742A (zh) * 2011-12-16 2013-06-19 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
CN104379575A (zh) * 2012-06-06 2015-02-25 Irm责任有限公司 用于调节egfr活性的化合物和组合物
CN104520291A (zh) * 2012-06-06 2015-04-15 Irm责任有限公司 用于调节egfr活性的化合物和组合物
CN105008371A (zh) * 2013-02-07 2015-10-28 默克专利股份公司 大环哒嗪酮衍生物
WO2018005860A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018112111A1 (en) * 2016-12-13 2018-06-21 Health Research, Inc. Epidermal growth factor receptor (egfr) targeted photosensitizers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TKI耐药后针对T790M突变治疗;王红等;《中国肺癌杂志》;第18卷(第4期);第245-250页 *

Also Published As

Publication number Publication date
US12522615B2 (en) 2026-01-13
CN114007698A (zh) 2022-02-01
EP3986564A1 (en) 2022-04-27
US20220380382A1 (en) 2022-12-01
JP2022538228A (ja) 2022-09-01
WO2020260252A1 (en) 2020-12-30
JP7590996B2 (ja) 2024-11-27

Similar Documents

Publication Publication Date Title
CN114007698B (zh) 作为egfr抑制剂的大环化合物和衍生物
US12545670B2 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
JP7313364B2 (ja) Ｅｇｆｒ阻害剤としての新たなベンズイミダゾール化合物および誘導体
AU2020296914A1 (en) Anticancer combination therapy
CN116507627B (zh) 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物
WO2018167019A1 (en) Tosylacetate based compounds and derivatives thereof as phgdh inhibitors
JP7285249B2 (ja) Ｃｄｋ８／ｃｄｋ１９阻害剤としての新規な［１，６］ナフチリジン化合物及び誘導体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant